H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ and H.C. Wainwright 6th Annual Neuro Perspectives ConferenceNEW YORK, May 14,…
With New Wins on Hand, Company Remains Positioned for Record Year of PerformanceLOUISVILLE, Ky., May 14, 2025 (GLOBE NEWSWIRE) --…
VERSATILE-003 Phase 3 Site Initiations Underway Multiple Abstracts Selected for Presentation at the 2025 American Society of Clinical Oncology Annual…
First Biomarker Analysis from Phase 1b Study of GT-02287 in Parkinson’s Disease Expected Mid-2025BETHESDA, Md., May 14, 2025 (GLOBE NEWSWIRE)…
Focused on evaluation of strategic alternatives, with restructuring and closure of the Netherlands operationsEnrollment in LAVA-1266 Phase 1 continues to…
HALIFAX, Nova Scotia, May 14, 2025 (GLOBE NEWSWIRE) -- Erdene Resource Development Corp. (TSX:ERD; MSE:ERDN) ("Erdene" or the "Company") is…
Imdusiran combination therapy has functionally cured 8 patients with chronic hepatitis B (cHBV) to date, including 2 patients who received…
- Interim data from ENERGY 3 trial highlight INZ-701’s potential to modify disease course in ENPP1 Deficiency, with sustained phosphate…
First quarter revenues of $46.5 million, in line with previous guidanceFirst quarter GAAP net loss of $5.1 million; non-GAAP net…
- Oxylanthanum carbonate (OLC) New Drug Application (NDA) for hyperphosphatemia in chronic kidney disease patients on dialysis under review by…
This website uses cookies.